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1. INTRODUCTION {#jcla22858-sec-0005}
===============

Lung cancer is the leading cause of cancer death worldwide, and 22% and 13.8% of cancer deaths in 2018 were estimated to be caused by lung cancer in men and women, respectively.[1](#jcla22858-bib-0001){ref-type="ref"} The corresponding percentages in China were 28% and 23% in 2012,[2](#jcla22858-bib-0002){ref-type="ref"} making it the most common cause of cancer death. Lung cancer is classified into two main categories: non‐small cell lung cancer (NSCLC), accounting for approximately 80% of all lung cancer cases, and small‐cell lung cancer (SCLC).[3](#jcla22858-bib-0003){ref-type="ref"} Although tobacco smoking is the major risk factor,[4](#jcla22858-bib-0004){ref-type="ref"} the etiology of lung cancer is multifactorial, including inherited genetic characteristics, such as single nucleotide polymorphisms (SNPs),[5](#jcla22858-bib-0005){ref-type="ref"} which explains individual\'s susceptibility to the development of lung cancer. During the past decade, genome‐wide association studies (GWAS) have identified many common SNPs associated with the risk and outcome of lung cancer. However, heritability analysis indicated that the identified genetic loci could explain only a small fraction of lung cancer susceptibility.[6](#jcla22858-bib-0006){ref-type="ref"} Additional efforts are needed to search for more lung cancer‐related genetic factors, especially those rare variants and loci in non‐coding regions.

Long non‐coding RNAs (lncRNAs) are a class of RNA transcripts with more than 200 nucleotides in length and without translational capability. LncRNAs have been found to have diverse biological functions, some of which are involved in various tumorigenic processes.[7](#jcla22858-bib-0007){ref-type="ref"} A number of dysregulated lncRNAs have also been demonstrated to be potential diagnostic or prognostic biomarkers for lung cancer, such as metastasis associated in lung adenocarcinoma transcript 1 (*MALAT1*)[8](#jcla22858-bib-0008){ref-type="ref"} and HOX antisense intergenic RNA (*HOTAIR*)[9](#jcla22858-bib-0009){ref-type="ref"} which are overexpressed in NSCLC and recognized as onco‐lncRNAs. In contrast, maternally expressed gene 3 (*MEG3*),[10](#jcla22858-bib-0010){ref-type="ref"} taurine‐upregulated gene 1 *(TUG1*),[11](#jcla22858-bib-0011){ref-type="ref"} and BRAF‐activated non‐protein coding RNA (*BANCR*)[12](#jcla22858-bib-0012){ref-type="ref"} which are downregulated in NSCLC are considered as tumor suppressors. These dysregulated lncRNAs are found to be involved in regulation of cell growth, proliferation, migration, and invasion.

Evidence also indicates that SNPs in the lncRNA genes affected tumorigenic process and chemotherapy response. Gong et al[13](#jcla22858-bib-0013){ref-type="ref"} found that SNPs in *HOTTIP*, *H19,* and *CCAT2* were associated with lung cancer risk, and SNPs in *MALAT1*, *H19*, *CCAT2*, *HOTAIR,* and *ANRIL* were related to lung cancer patients' response to platinum‐based chemotherapy. Yuan et al[14](#jcla22858-bib-0014){ref-type="ref"} conducted a meta‐analysis of eight GWAS on subjects with European ancestry and discovered rs114020893 in the lncRNA *NEXN‐AS1* associated with lung cancer risk. This SNP\'s influence on lung cancer susceptibility may be achieved through its genotype‐specific secondary structure stability. Hu et al[15](#jcla22858-bib-0015){ref-type="ref"} reported a SNP in *CASC8* associated with both lung cancer risk and chemotherapy response and toxicity.

Findings from the above studies indicate that identifying SNPs in the lncRNA genes associated with lung cancer may help to elucidate the biological mechanisms of lncRNAs in lung cancer. Currently, our knowledge on lncRNA\'s involvement in lung cancer is still limited; more studies are needed to discover SNPs in lncRNAs which are associated with lung cancer risk or outcome. Based on the findings of our previous study on lncRNAs in NSCLC,[16](#jcla22858-bib-0016){ref-type="ref"} we conducted a case‐control study on SNPs of the lncRNAs which showed different expression between tumor and matched adjacent normal tissues. In this study, we analyzed the association of lung cancer with 17 SNPs in 13 selected lncRNAs. We also investigated these SNPs in relation to lung cancer survival. Results of our association study are described in this report.

2. MATERIALS AND METHODS {#jcla22858-sec-0006}
========================

2.1. Study subjects {#jcla22858-sec-0007}
-------------------

The case‐control study included 1294 NSCLC cases and 1729 healthy controls who were recruited between April 2011 and July 2015 from the China Medical University. The cases were newly diagnosed patients with histologically confirmed primary NSCLC who had no previous diagnosis of cancer or treatment of radiotherapy and chemotherapy. The cases were followed after surgery until August 2017 through clinical visits and regular telephone contacts. The control subjects were identified and enrolled in the study from the same or nearby communities where the cases resided. The controls had no medical history of cancer at the time of case diagnosis. All the study subjects were genetically unrelated Chinese with Han ethnicity. The study was approved by the Medical Ethics Committees of Human Studies at China Medical University. Written informed consents were obtained from all the subjects.

2.2. SNP selection and genotyping {#jcla22858-sec-0008}
---------------------------------

In our previous study,[16](#jcla22858-bib-0016){ref-type="ref"} we found 153 lncRNAs, which had significant differences in expression (fold change \>2) between tumor and matched adjacent tissues. Based on the list, we searched NCBI dbSNP (<http://www.ncbi.nlm.nih.gov/>), HapMap (<http://www.hapmap.org>), and lncRNASNP (<http://bioinfo.life.hust.edu.cn/lncRNASNP/>) and identified 3765 SNPs. Considering that polymorphisms in the non‐coding regions may affect the binding of other transcripts such as microRNAs,[17](#jcla22858-bib-0017){ref-type="ref"} we selected SNPs located in the binding sites which may alter the binding affinity of lncRNAs to other molecules. The following selection criteria were established to choose SNPs for genotyping: (a) minor allele frequency (MAF) reported in HapMap ≥5% in Chinese Han, Beijing (CHB); (b) located in the regulatory region of genes; and (c) affecting the binding with microRNAs. Following the criteria, we selected 17 SNPs for study (Table [1](#jcla22858-tbl-0001){ref-type="table"}).

###### 

Information on 17 SNPs in the 13 lncRNA genes

  Rs number    Gene                  Locus      Location    Base change   MAF in controls   HWE *P*
  ------------ --------------------- ---------- ----------- ------------- ----------------- ---------
  rs10889184   LINC01748             1p32.1     60540378    G/A           0.45              0.622
  rs3113503    LINC00607/LINC01614   2q35       215719150   G/C           0.33              0.849
  rs498238     LINC01833             2p21       44921691    C/T           0.12              0.624
  rs496467     LINC01833             2p21       44921864    A/G           0.49              0.702
  rs13431201   LINC01833             2p21       44922015    C/G           0.06              0.440
  rs1992825    LINC01833             2p21       44923139    G/C           0.32              0.242
  rs517055     LINC01833             2p21       44923338    A/T           0.49              0.573
  rs1466099    RNF144A‐AS1           2p25.2     6917071     G/A           0.26              0.819
  rs62288095   LINC00887             3q29       194303359   C/A           0.11              0.512
  rs6830064    LINC02466             4q28.2     129725387   T/G           0.18              0.694
  rs7678341    lnc‐RCHY1‐3:1         4q13.3     75269312    G/A           0.23              0.541
  rs16901995   lnc‐NDUFS6‐5:5        5p15.33    1933867     C/T           0.42              0.978
  rs4077205    LOC100128340          5q35.3     177957648   A/G           0.70              0.107
  rs35132843   CASC21/CASC8          8q24.21    127289874   T/G           0.37              0.087
  rs10734387   BBOX1‐AS1             11p14.2    27151108    C/T           0.30              0.638
  rs1867299    HOXC13‐AS             12q13.13   53936191    T/C           0.18              0.135
  rs219741     LOC105369301          21q22.13   36480738    G/A           0.10              0.716

HWE, Hardy‐Weinberg equilibrium; MAF, Minor allele frequency.
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Our genotyping method has been described elsewhere.[18](#jcla22858-bib-0018){ref-type="ref"} In brief, genomic DNA in peripheral blood leukocytes was extracted from cases and controls using the standard phenol‐chloroform method. SNP genotyping was determined by the TaqMan assay using the ABI 7900 FAST real‐time polymerase chain reaction (PCR) system (Thermo Fisher Scientific, Waltham, MA, USA). All primers and probes were purchased from Thermo Fisher Scientific. Ten percent of the DNA samples were randomly selected for replication, and the results of the repeats were in complete concordance.

2.3. Statistical analysis {#jcla22858-sec-0009}
-------------------------

Distributions of subject characteristics and genetic polymorphisms were compared between cases and controls using the chi‐square test. Student *t* test was used for comparison of continues variables between groups. Hardy‐Weinberg equilibrium was calculated for each SNP in the control subjects. In order to balance the distributions of age and gender in case and control groups, propensity score matching (PSM) analysis was conducted. Associations between SNPs and NSCLC risk were analyzed using the unconditional logistic regression model. Odds ratios (OR) and 95% confidence interval (CI) were calculated in the regression model, and the analyses were adjusted for confounding factors (age, gender, and smoking status). Subgroup analyses were also performed for each polymorphism to assess potential gene‐environment interaction or joint effect. Survival time was defined as the time interval from the date of NSCLC diagnosis to the date of death or end of follow‐up. Median survival time (MST) was the time point when 50% of the patients were dead. Kaplan‐Meier survival analysis and log‐rank test were used to compare differences in survival time by SNP genotypes. Associations between SNPs and overall survival were analyzed using the Cox proportional hazards regression model in which hazard ratios (HR) and 95%CI were estimated. *P* values reported were two‐tailed, and *P *\< 0.05 was considered statistically significant. All data analyses were performed using the SPSS software version 19.0 (IBM, Armonk, NY, USA). We also selected the NCBI data sets, GSE19804 and GSE18842, for analysis of gene expression. The scatter plots were generated using the GraphPad Prism 6.0 software (GraphPad Software, San Diego, CA, USA).

3. RESULTS {#jcla22858-sec-0010}
==========

3.1. Study population {#jcla22858-sec-0011}
---------------------

The demographic characteristics of the initial 1294 cases and 1729 controls were summarized in Table [S1](#jcla22858-sup-0001){ref-type="supplementary-material"}. In order to balance the age and gender differences between cases and controls, we conducted PSM. First, we deleted subjects with missing values in gender and age, which left us with 1169 NSCLC cases and 1354 controls. Then, a propensity score (PS) was constructed to quantify each subject\'s gender and age. The cases were later matched to controls by PS. After PSM, we obtained well‐balanced distributions of demographic characteristics between cases and controls (Table [2](#jcla22858-tbl-0002){ref-type="table"}). The age (*P* = 0.310) and gender (*P* = 0.326) were no longer significantly different. There were more smokers in cases than in controls (48.07% vs 25.37%).

###### 

Distribution of the selected characteristics in cases and controls after PSM

  Variables                                                N (%)          *P* value[\*](#jcla22858-note-0003){ref-type="fn"}   
  -------------------------------------------------------- -------------- ---------------------------------------------------- ---------
  Gender                                                   1169 (100%)    1005 (100%)                                          0.326
  Male                                                     579 (49.53%)   519 (51.64%)                                         
  Female                                                   590 (50.47%)   486 (48.36%)                                         
  Age                                                      1169 (100%)    1005 (100%)                                          0.310
  \<60                                                     584 (49.96%)   524 (52.14%)                                         
  ≥60                                                      585 (50.04%)   481 (47.86%)                                         
  Smoking status[a](#jcla22858-note-0002){ref-type="fn"}   1165 (100%)    1001 (100%)                                          \<0.001
  Non‐smoker                                               605 (51.93%)   747 (74.63%)                                         
  Ever‐smoker                                              560 (48.07%)   254 (25.37%)                                         

Due to the missing values, the numbers of cases and controls were less than 1169 and 1005, respectively.

Two‐side chi‐squared test.
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3.2. Associations of SNPs and NSCLC risk {#jcla22858-sec-0012}
----------------------------------------

Allele distributions of the 17 SNPs selected for study were all in Hardy‐Weinberg equilibrium in the control group (*P* \> 0.05, Table [1](#jcla22858-tbl-0001){ref-type="table"}). After PSM, genotype distributions of the 17 SNPs and their associations with NSCLC risk in different inheritance models (dominant, recessive, and additive) are shown in Tables [S2](#jcla22858-sup-0001){ref-type="supplementary-material"} and [3](#jcla22858-tbl-0003){ref-type="table"}. Potential gene‐environment interaction was assessed for each polymorphism in the initial study population stratified by the environmental factor of interest (Table [4](#jcla22858-tbl-0004){ref-type="table"}). Significant associations with NSCLC were suggested for three SNPs, including rs498238, rs16901995, and rs219741.

###### 

Associations between selected SNPs and NSCLC risk after PSM

  Genotypes               N (%)           *P* value[\*](#jcla22858-note-0006){ref-type="fn"}   Crude OR (95%CI)   Adjusted OR (95%CI)[\*](#jcla22858-note-0003){ref-type="fn"}, [a](#jcla22858-note-0005){ref-type="fn"}   
  ----------------------- --------------- ---------------------------------------------------- ------------------ -------------------------------------------------------------------------------------------------------- ----------------------
  **rs3113503 (G\>C)**    1012 (100%)     979 (100%)                                           0.050                                                                                                                       
  GG                      432 (42.69%)    448 (45.76%)                                                            1.00                                                                                                     1.00
  GC                      489 (48.32%)    423 (43.21%)                                                            1.20 (1.00‐1.44)                                                                                         **1.22 (1.01‐1.49)**
  CC                      91 (8.99%)      108 (11.03%)                                                            0.87 (0.64‐1.19)                                                                                         0.81 (0.59‐1.13)
  Dominant model          1012 (100%)     979 (100%)                                           0.167                                                                                                                       
  GG                      432 (42.69%)    448 (45.76%)                                                            1.00                                                                                                     1.00
  GC + CC                 580 (57.31%)    531 (54.24%)                                                            1.13 (0.95‐1.35)                                                                                         1.14 (0.94‐1.37)
  Recessive model         1012 (100%)     979 (100%)                                           0.129                                                                                                                       
  GG + GC                 921 (91.01%)    871 (88.97%)                                                            1.00                                                                                                     1.00
  CC                      91 (8.99%)      108 (11.03%)                                                            0.80 (0.59‐1.07)                                                                                         **0.74 (0.54‐1.00)**
  **rs498238 (C\>T)**     1005 (100%)     961 (100%)                                           0.188                                                                                                                       
  CC                      791 (78.71%)    745 (77.52%)                                                            1.00                                                                                                     1.00
  CT                      209 (20.80%)    204 (21.23%)                                                            0.97 (0.78‐1.20)                                                                                         0.97 (0.77‐1.22)
  TT                      5 (0.50%)       12 (1.25%)                                                              0.39 (0.14‐1.12)                                                                                         **0.33 (0.11‐0.97)**
  Dominant model          1005 (100%)     961 (100%)                                           0.526                                                                                                                       
  CC                      791 (78.71%)    745 (77.52%)                                                            1.00                                                                                                     1.00
  CT + TT                 214 (21.29%)    216 (22.48%)                                                            0.93 (0.75‐1.16)                                                                                         0.93 (0.74‐1.16)
  Recessive model         1005 (100%)     961 (100%)                                           0.072                                                                                                                       
  CC + CT                 1000 (99.50%)   949 (98.75%)                                                            1.00                                                                                                     1.00
  TT                      5 (0.50%)       12 (1.25%)                                                              0.40 (0.14‐1.13)                                                                                         **0.33 (0.11‐0.97)**
  **rs16901995 (C\>T)**   1096 (100%)     984 (100%)                                           0.413                                                                                                                       
  CC                      380 (34.67%)    322 (32.72%)                                                            1.00                                                                                                     1.00
  CT                      532 (48.54%)    477 (48.48%)                                                            0.95 (0.78‐1.15)                                                                                         0.94 (0.77‐1.15)
  TT                      184 (16.79%)    185 (18.80%)                                                            0.84 (0.66‐1.09)                                                                                         0.78 (0.59‐1.01)
  Dominant model          1096 (100%)     984 (100%)                                           0.348                                                                                                                       
  CC                      380 (34.67%)    322 (32.72%)                                                            1.00                                                                                                     1.00
  CT + TT                 716 (65.33%)    662 (67.28%)                                                            0.92 (0.76‐1.10)                                                                                         0.89 (0.74‐1.08)
  Recessive model         1096 (100%)     984 (100%)                                           0.230                                                                                                                       
  CC + CT                 912 (83.21%)    799 (81.20%)                                                            1.00                                                                                                     1.00
  TT                      184 (16.79%)    185 (18.80%)                                                            0.87 (0.70‐1.09)                                                                                         0.80 (0.63‐1.02)
  **rs219741 (G\>A)**     1056 (100%)     955 (100%)                                           0.325                                                                                                                       
  GG                      813 (76.99%)    753 (78.85%)                                                            1.00                                                                                                     1.00
  GA                      235 (22.25%)    191 (20.00%)                                                            1.14 (0.92‐1.41)                                                                                         1.08 (0.86‐1.35)
  AA                      8 (0.76%)       11 (1.15%)                                                              0.67 (0.27‐1.68)                                                                                         0.60 (0.23‐1.56)
  Dominant model          1056 (100%)     955 (100%)                                           0.316                                                                                                                       
  GG                      813 (76.99%)    753 (78.85%)                                                            1.00                                                                                                     1.00
  GA + AA                 243 (23.01%)    202 (21.15%)                                                            1.11 (0.90‐1.38)                                                                                         1.05 (0.84‐1.31)
  Recessive model         1056 (100%)     955 (100%)                                           0.361                                                                                                                       
  GG + GA                 1048 (99.24%)   944 (98.85%)                                                            1.00                                                                                                     1.00
  AA                      8 (0.76%)       11 (1.15%)                                                              0.66 (0.26‐1.64)                                                                                         0.59 (0.23‐1.53)

Bold OR values indicated *P* \< 0.05.

Adjusted for age, gender, and smoking status.

Two‐side chi‐squared test.
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###### 

Associations between SNPs and NSCLC risk stratified by selected variables

  Genetic Variant   Variables   Genotypes (Cases/Controls)   *P* value[a](#jcla22858-note-0008){ref-type="fn"}   Dominant model (AB + BB)/AA OR (95%CI)[a](#jcla22858-note-0008){ref-type="fn"}
  ----------------- ----------- ---------------------------- --------------------------------------------------- --------------------------------------------------------------------------------
  rs3113503         Gender                                                                                       
  Male              231/235     280/338                      0.370                                               0.88 (0.67‐1.16)
  Female            202/463     301/511                      0.054                                               1.29 (1.00‐1.66)
  Age                                                                                                            
  \<60              225/390     273/458                      0.877                                               0.98 (0.74‐1.30)
  ≥60               207/204     307/269                      0.196                                               1.20 (0.91‐1.57)
  Smoking status                                                                                                 
  Non‐smoker        221/641     302/765                      0.373                                               1.11 (0.88‐1.39)
  Ever‐smoker       215/120     276/148                      0.589                                               1.09 (0.80‐1.48)
  rs498238          Gender                                                                                       
  Male              391/426     114/139                      0.662                                               0.93 (0.67‐1.29)
  Female            402/754     100/192                      0.711                                               0.94 (0.69‐1.29)
  Age                                                                                                            
  \<60              390/648     107/171                      0.518                                               0.89 (0.63‐1.26)
  ≥60               401/362     107/108                      0.623                                               0.92 (0.67‐1.27)
  Smoking status                                                                                                 
  Non‐smoker        410/1081    107/295                      0.936                                               0.99 (0.75‐1.31)
  Ever‐smoker       385/200     105/64                       0.334                                               0.84 (0.58‐1.20)
  rs16901995        Gender                                                                                       
  Male              177/180     371/396                      0.918                                               0.99 (0.74‐1.31)
  Female            204/333     346/648                      0.202                                               0.85 (0.66‐1.09)
  Age                                                                                                            
  \<60              195/278     346/577                      0.076                                               0.77 (0.58‐1.03)
  ≥60               185/154     370/321                      0.698                                               1.06 (0.80‐1.40)
  Smoking status                                                                                                 
  Non‐smoker        212/469     354/950                      **0.035**                                           **0.78 (0.62‐0.98)**
  Ever‐smoker       168/89      364/180                      0.679                                               1.07 (0.78‐1.48)
  rs219741          Gender                                                                                       
  Male              407/456     127/109                      0.617                                               1.09 (0.79‐1.50)
  Female            408/747     116/168                      0.651                                               1.07 (0.79‐1.46)
  Age                                                                                                            
  \<60              405/676     119/125                      **0.033**                                           **1.47 (1.03‐2.10)**
  ≥60               408/351     124/119                      0.433                                               0.88 (0.65‐1.20)
  Smoking status                                                                                                 
  Non‐smoker        420/1096    121/238                      0.400                                               1.13 (0.86‐1.48)
  Ever‐smoker       395/210     122/59                       0.933                                               1.02 (0.71‐1.45)

Bold OR values indicated *P* \< 0.05.

Adjusted for age, gender, and smoking status when properly.

A stands for major allele and B stands for minor allele.
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For SNP rs498238, individuals with the TT homozygous genotype had a lower risk of NSCLC compared to those with the CC homozygous genotype after age, gender, and smoking status were adjusted in the analysis (adjusted OR = 0.33, 95%CI: 0.11‐0.97, *P* = 0.043; Table [3](#jcla22858-tbl-0003){ref-type="table"}). The association between rs498238 and NSCLC mainly came from the recessive model, and no significant association was seen in the dominant model.

SNP rs16901995 was not associated with NSCLC in overall analysis, but in the stratified analysis it was shown that in non‐smokers, individuals with CT or TT genotypes had a reduced risk for NSCLC compared to those with CC genotype (adjusted OR = 0.78, 95%CI: 0.62‐0.98, *P* = 0.035; Table [4](#jcla22858-tbl-0004){ref-type="table"}). Similarly, when analyzing the relationship in subgroups, we found that SNP rs219741 was associated with increased risk of NSCLC among younger subjects (age \< 60 years). The adjusted OR was 1.47, and 95%CI was between 1.03 and 2.10 (*P* = 0.033).

SNP rs3113503 showed controversial results. Individuals with GC genotype had an increased risk compared to those with wild GG genotype (adjusted OR = 1.22, 95%CI: 1.01‐1.49, *P* = 0.035). But subjects with CC genotype had a reduced risk in a recessive model (adjusted OR = 0.74, 95%CI: 0.54‐1.00, *P* = 0.050). There was no significant difference in the dominant model, nor in stratified analyses.

3.3. Associations of SNPs and NSCLC outcome {#jcla22858-sec-0013}
-------------------------------------------

Patient characteristics and clinical features are shown in Table [S3](#jcla22858-sup-0001){ref-type="supplementary-material"}. Survival analysis was performed to assess the genotypes of the four selected SNPs in association with the NSCLC outcome (Table [5](#jcla22858-tbl-0005){ref-type="table"}). The analysis showed no significant associations between these genotypes and NSCLC overall survival before or after adjustment for age, gender, smoking status, disease stage, and histology type. To further investigate the association of SNPs with NSCLC survival in patients with different clinical characteristics, we conducted stratification analyses in the dominant model (Table [S4](#jcla22858-sup-0001){ref-type="supplementary-material"}). The results showed that only in patients with lung adenosquamous carcinoma (ASC), rs219741 was associated with survival. However, the sample size (deaths/patients: 19/23 vs 5/6, in GG vs GA + AA genotypes, respectively) was too small to draw a conclusion.

###### 

Associations between SNPs and NSCLC survival

  Genotypes         Patients   Deaths   MST (mo) (95%CI)      Log‐rank *P*   HR (95%CI)         HR (95%CI)[a](#jcla22858-note-0010){ref-type="fn"}
  ----------------- ---------- -------- --------------------- -------------- ------------------ ----------------------------------------------------
  **rs3113503**     746        457                            0.955                             
  GG                326        198      29.43 (23.45‐35.42)                  1.00               1.00
  CG                351        215      29.33 (23.60‐35.06)                  1.03 (0.85‐1.25)   1.03 (0.84‐1.26)
  CC                69         44       29.40 (21.22‐37.58)                  1.02 (0.74‐1.42)   1.05 (0.74‐1.48)
  Dominant model                                              0.764                             
  GG                326        198      29.43 (23.45‐35.42)                  1.00               1.00
  CG + CC           420        259      29.37 (24.32‐34.42)                  1.03 (0.86‐1.24)   1.03 (0.85‐1.25)
  Recessive model                                             0.963                             
  GG + CG           677        413      29.33 (25.02‐33.64)                  1.00               1.00
  CC                69         44       29.40 (21.22‐37.58)                  1.01 (0.74‐1.38)   1.03 (0.74‐1.44)
  **rs219741**      777        467                            0.500                             
  GG                610        359      31.97 (26.69‐37.25)                  1.00               1.00
  AG                161        104      28.80 (22.88‐34.73)                  1.14 (0.92‐1.42)   1.10 (0.88‐1.39)
  AA                6          4        29.37 (22.73‐36.00)                  1.02 (0.38‐2.74)   1.11 (0.41‐2.99)
  Dominant model                                              0.248                             
  GG                610        359      31.97 (26.69‐37.25)                  1.00               1.00
  AG + AA           168        109      29.27 (25.06‐33.48)                  1.14 (0.92‐1.41)   1.11 (0.88‐1.38)
  Recessive model                                             0.992                             
  GG + AG           771        463      31.00 (27.03‐34.97)                  1.00               1.00
  AA                6          4        29.37 (22.73‐36.00)                  1.00 (0.37‐2.66)   1.09 (0.41‐2.93)
  **rs498238**      737        448                            0.902                             
  CC                574        353      29.40 (24.44‐34.36)                  1.00               1.00
  TC                158        91       32.33 (25.43‐39.24)                  0.98 (0.77‐1.23)   1.02 (0.80‐1.30)
  TT                5          4        28.30 (6.68‐49.92)                   1.22 (0.45‐3.26)   0.83 (0.31‐2.24)
  Dominant model                                              0.884                             
  CC                574        353      29.40 (24.44‐34.36)                  1.00               1.00
  CC + TC           163        95       32.33 (25.64‐39.03)                  0.98 (0.78‐1.23)   1.01 (0.79‐1.28)
  Recessive model                                             0.689                             
  CC + TC           732        444      29.97 (26.02‐33.91)                  1.00               1.00
  TT                5          4        28.30 (6.68‐49.92)                   1.22 (0.46‐3.27)   0.83 (0.31‐2.23)
  **rs16901995**    810        499                            0.690                             
  CC                294        182      27.23 (23.06‐31.40)                  1.00               1.00
  CT                386        239      33.00 (26.27‐39.73)                  0.94 (0.77‐1.14)   0.98 (0.80‐1.21)
  TT                130        78       29.97 (22.49‐37.44)                  0.90 (0.70‐1.17)   0.96 (0.73‐1.28)
  Dominant model                                              0.421                             
  CC                294        182      27.23 (23.06‐31.40)                  1.00               1.00
  CT + TT           516        317      32.53 (27.80‐37.27)                  0.93 (0.77‐1.11)   0.98 (0.81‐1.19)
  Recessive model                                             0.580                             
  CC + CT           680        421      28.80 (24.85‐32.75)                  1.00               1.00
  TT                130        78       29.97 (22.49‐37.44)                  0.93 (0.73‐1.19)   0.97 (0.75‐1.26）

Adjusted for age, gender, smoking status, disease stage, and histology type.
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4. DISCUSSION {#jcla22858-sec-0014}
=============

In this study, we evaluated 17 SNPs in 13 lncRNAs with regard to their associations with NSCLC risk and survival. We found that NSCLC risk was significantly associated with SNP rs3113503, rs498238, rs16901995, and rs219741. These SNPs are located in different lncRNA genes and appeared to have different associations with NSCLC. While SNP rs219741 was associated with an increased risk in younger population, SNP rs498238 and rs16901995 were linked to a reduced risk of NSCLC. SNP rs3113503 had a conflicting relationship with NSCLC risk.

Although the biological implications of these SNPs in the lncRNA genes are unknown, our understanding of lncRNA\'s involvement in cancer is rapidly expanding in recent years. The biological function of lncRNA largely depends on their subcellular localization. In cytoplasm, lncRNAs behave like competitive endogenous RNA to bind mRNAs, suppressing translation or degradation of targeted mRNAs. When in nucleus, lncRNAs serve as scaffold to form, for example, a chromatin modification complex, or act as decoy to suppress the function of other transcripts, such as microRNAs. Some lncRNAs tether transcription factors to gene promoters.[7](#jcla22858-bib-0007){ref-type="ref"} Recently, lncRNAs are found to contain codes for functional micropeptides based on small‐ORFs (Open Reading Frames).[19](#jcla22858-bib-0019){ref-type="ref"} LncRNAs may also play roles in intercellular communication.[20](#jcla22858-bib-0020){ref-type="ref"} Since 80% of SNPs associated with cancer are located in the non‐coding regions,[21](#jcla22858-bib-0021){ref-type="ref"} many of them are likely to be in lncRNAs.[22](#jcla22858-bib-0022){ref-type="ref"}, [23](#jcla22858-bib-0023){ref-type="ref"} Studies have shown that SNPs in the lncRNA genes can influence cancer through different biological mechanisms. For example, SNPs can affect the expression of their relevant lncRNAs.[24](#jcla22858-bib-0024){ref-type="ref"} Different SNP genotype in *LINC00673* may affect its binding to *miR‐1231*, which alters the miRNA\'s activity and influences PTPN11 (protein tyrosine phosphatase, non‐receptor type 11) degradation in an allele‐specific manner.[25](#jcla22858-bib-0025){ref-type="ref"} Genetic polymorphisms can also affect the expression of lncRNAs through allele‐specific modulation of their distal regulatory elements. A SNP located in a distal enhancer of lncRNA *PCAT1* (prostate cancer associated transcript 1) alters the binding of its transcription factors ONECUT2 (one cut homeobox 2) and androgen receptor (AR) to the enhancer and *PCAT1* promoter, thereby affecting the expression of *PCAT1* which is involved in the development and progression of prostate cancer.[26](#jcla22858-bib-0026){ref-type="ref"}

SNP rs498238 is located in the fourth exon of the long intergenic non‐coding RNA 1833 gene (*LINC01833*), and the lncRNA, initially named as *loc100130502*, is predicted to stay mainly in the nucleus of A549 cells.[27](#jcla22858-bib-0027){ref-type="ref"} In the NCBI GEO database, *loc100130502* was shown to be upregulated in NSCLC tumors compared to matched adjacent non‐tumor tissues of non‐smoking women in one dataset GSE19804 (Figure [1](#jcla22858-fig-0001){ref-type="fig"}A), but no difference in another dataset GSE18842 (Figure [1](#jcla22858-fig-0001){ref-type="fig"}B). The *LINC01833* gene is located close to the gene *SIX3*, and this non‐coding transcript is considered a Wnt/β‐catenin pathway‐related lncRNA.[28](#jcla22858-bib-0028){ref-type="ref"} SIX3 was reported to inhibit the pathway in the development of vertebrate forebrain.[29](#jcla22858-bib-0029){ref-type="ref"} Kumar et al[30](#jcla22858-bib-0030){ref-type="ref"} found that SIX3 acted as a corepressor of *Wnt* and suppressed its transcription in breast cancer. In addition, in vivo binding assay revealed that SIX3 repressed Wnt1 expression by binding to its 3′ enhancer and to the elements located within its 5′ promoter region.[31](#jcla22858-bib-0031){ref-type="ref"} SIX3 was downregulated in lung adenocarcinoma tissues compared their matched adjacent normal tissues. Restoration of SIX3 expression in lung cancer cells with low endogenous SIX3 resulted in suppressed cell proliferation and migration. Moreover, high expression of SIX3 was associated with improved overall and progression‐free survival of patients with lung adenocarcinoma.[32](#jcla22858-bib-0032){ref-type="ref"} A similar finding was also observed in patients with glioblastoma.[33](#jcla22858-bib-0033){ref-type="ref"} A meta‐analysis suggests that SIX3 may play a role in suppressing the progression of lung cancer, especially in its early stage.[34](#jcla22858-bib-0034){ref-type="ref"}

![Scatter plots of relative lncRNA levels in NSCLC tumor and adjacent non‐tumor tissues. LOC100130502 in GSE19804 (A) and GSE18842 (B). LINC00607 in GSE19804 (C) and GSE18842 (D). Rs219741 G\>A change in lnc‐CHAF1B‐3:1, genotype G (WT) (E), and genotype A (MT) (F). \*\*\**P* \< 0.0001](JCLA-33-e22858-g001){#jcla22858-fig-0001}

SNP rs3113503 is an intron variant which is located in a gene encoding two long non‐coding transcripts, including a shorter lncRNA named *LINC01614* and a longer one called *LINC00607*. *LINC00607* is present mainly in cell nucleus,[27](#jcla22858-bib-0027){ref-type="ref"} and significant downregulation was observed in NSCLC when we analyzed the online datasets GSE19804 (Figure [1](#jcla22858-fig-0001){ref-type="fig"}C) and GSE18842 (Figure [1](#jcla22858-fig-0001){ref-type="fig"}D). No expression information was found for *lnc‐NDUFS6‐5:5* (rs16901995) and *loc105369301* (rs219741). LncRNASNP database indicates that SNP rs219741 may change the secondary structure of the lncRNA *lnc‐CHAF1B‐3:1* (Figure [1](#jcla22858-fig-0001){ref-type="fig"}E for wild type and Figure [1](#jcla22858-fig-0001){ref-type="fig"}F for mutant type). Our data suggest that SNP rs498238 and rs3113503 may have allele‐specific influences on lncRNA expression in NSCLC.

The SNPs we investigated in this study were selected from a list of lncRNAs which showed significant differences in expression between NSCLC tumor and matched adjacent normal tissues. The initial analysis of lncRNAs was accomplished with an expression microarray, and the study population was Chinese Han. Thus, the findings of our SNP analysis were likely to be limited to Chinese populations and the number of lncRNAs included in the microarray chip. In addition to these limitations, our sample size for analyzing the SNP association was relatively small, and there were no validation and *P* value adjustment during our evaluation. We also did not perform any functional evaluation and experiments to demonstrate the biological relevance of these SNPs in NSCLC. Despite these shortcomings, we were able to find some preliminary data to suggest that SNPs in non‐coding regions, especially in the lncRNA genes, may have potential implications in cancer etiology. More studies are needed to characterize these non‐coding region SNPs and elucidate their biological relevance and molecular mechanisms in relation to lncRNA\'s function and tumorigenesis.

In summary, we analyzed 17 SNPs in the genes of lncRNAs with differential expression in NSCLC and identified three of them associated with the risk of NSCLC among Chinese. These findings suggest that SNPs in non‐coding regions of the genome may also be important when comparing to those in the coding regions. Further analyzing this type of SNPs may provide new insights into the functions of lncRNAs and their involvement in cancer.
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